Shirakata Yoshinori, Setoguchi Takashi, Machigashira Miho, Matsuyama Takashi, Furuichi Yasushi, Hasegawa Kozue, Yoshimoto Takehiko, Izumi Yuichi
Department of Periodontology, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan.
J Periodontol. 2008 Jan;79(1):25-32. doi: 10.1902/jop.2008.070141.
Regeneration of lost periodontium is the ultimate goal of periodontal therapy. Bone grafts, guided tissue regeneration, and application of growth factors are used for periodontal regeneration. This study aimed to evaluate the clinical efficacy of a new, injectable calcium phosphate bone cement (CPC) in human periodontal intrabony defects.
Thirty subjects (mean age, 53.4 +/- 9.1 years) with periodontitis and narrow intrabony defects were enrolled in the study. Subjects were classified randomly into the CPC graft group (N = 15) or the open flap debridement (OFD) alone group (N = 15). Clinical measurements were performed at baseline and at 3, 6, 9, and 12 months; radiographs were taken at baseline, 2 weeks, and 6 and 12 months after surgery. The Student t test was used for statistical analysis.
In the CPC group, six cases showed exposure or loss of the CPC within 12 months, whereas the remaining nine cases (CPC-R group) showed no adverse reaction, including infection or suppuration. Overall, CPC-R and OFD treatment groups exhibited a significant reduction in probing depth and a significant gain in clinical attachment level at 3, 6, 9, and 12 months compared to baseline values. However, there were no significant differences in any of the clinical parameters between the groups. In the CPC-R group, radiographic bone level gain appeared to be greater than in the OFD group.
The present study failed to demonstrate any superior clinical outcomes for the CPC group compared to the OFD group; however, radiographs revealed more favorable results in the CPC-R group. The filling volume and stiffness of CPC may compromise the clinical outcomes for periodontal intrabony defects.
缺失牙周组织的再生是牙周治疗的最终目标。骨移植、引导组织再生和生长因子的应用被用于牙周组织再生。本研究旨在评估一种新型可注射磷酸钙骨水泥(CPC)在人类牙周骨内缺损中的临床疗效。
30名患有牙周炎且骨内缺损狭窄的受试者(平均年龄53.4±9.1岁)被纳入研究。受试者被随机分为CPC移植组(N = 15)或单纯开放性翻瓣清创术(OFD)组(N = 15)。在基线以及3、6、9和12个月时进行临床测量;在基线、术后2周、6个月和12个月时拍摄X线片。采用Student t检验进行统计学分析。
在CPC组中,6例在12个月内出现CPC暴露或流失,而其余9例(CPC-R组)未出现包括感染或化脓在内的不良反应。总体而言,与基线值相比,CPC-R组和OFD治疗组在3、6、9和12个月时探诊深度均显著降低,临床附着水平显著增加。然而,两组之间的任何临床参数均无显著差异。在CPC-R组中,X线片显示的骨水平增加似乎大于OFD组。
本研究未能证明CPC组与OFD组相比有任何更优的临床结果;然而,X线片显示CPC-R组的结果更有利。CPC的填充量和硬度可能会影响牙周骨内缺损的临床结果。